WallStreetZenWallStreetZen

NASDAQ: ALXO
Alx Oncology Holdings Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their ALXO stock forecasts and price targets.

Forecast return on equity

Is ALXO forecast to generate an efficient return?

Company
-61.72%
Industry
252.48%
Market
227.91%
ALXO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ALXO forecast to generate an efficient return on assets?

Company
-33.43%
Industry
90.65%
ALXO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ALXO earnings per share forecast

What is ALXO's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$1.86
Avg 2 year Forecast
-$1.15
Avg 3 year Forecast
-$0.73

ALXO revenue forecast

What is ALXO's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

ALXO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ALXO$1.47N/AN/A
ACRV$2.53$13.50+433.60%Buy
TVGN$0.40$5.00+1,137.62%Strong Buy
COEP$15.13N/AN/A
ARTV$3.30$18.67+465.67%Buy
View Top Biotech Stocks

Alx Oncology Holdings Stock Forecast FAQ

What is ALXO's earnings growth forecast for 2025-2027?

(NASDAQ: ALXO) Alx Oncology Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.6%.

Alx Oncology Holdings's earnings in 2025 is -$108,010,000.On average, 6 Wall Street analysts forecast ALXO's earnings for 2025 to be -$100,650,297, with the lowest ALXO earnings forecast at -$99,359,909, and the highest ALXO earnings forecast at -$100,764,155. On average, 6 Wall Street analysts forecast ALXO's earnings for 2026 to be -$62,079,611, with the lowest ALXO earnings forecast at -$86,607,835, and the highest ALXO earnings forecast at -$48,389,566.

In 2027, ALXO is forecast to generate -$39,449,018 in earnings, with the lowest earnings forecast at -$46,226,268 and the highest earnings forecast at -$27,325,873.

If you're new to stock investing, here's how to buy Alx Oncology Holdings stock.

What is ALXO's revenue growth forecast for 2025-2027?

(NASDAQ: ALXO) Alx Oncology Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.61%.

Alx Oncology Holdings's revenue in 2025 is $0.On average, 6 Wall Street analysts forecast ALXO's revenue for 2025 to be $0, with the lowest ALXO revenue forecast at $0, and the highest ALXO revenue forecast at $0. On average, 6 Wall Street analysts forecast ALXO's revenue for 2026 to be $0, with the lowest ALXO revenue forecast at $0, and the highest ALXO revenue forecast at $0.

In 2027, ALXO is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is ALXO's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ALXO) forecast ROA is -33.43%, which is lower than the forecast US Biotechnology industry average of 90.65%.

What is ALXO's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ALXO) Alx Oncology Holdings's current Earnings Per Share (EPS) is -$2.01. On average, analysts forecast that ALXO's EPS will be -$1.86 for 2025, with the lowest EPS forecast at -$1.83, and the highest EPS forecast at -$1.86. On average, analysts forecast that ALXO's EPS will be -$1.15 for 2026, with the lowest EPS forecast at -$1.60, and the highest EPS forecast at -$0.89. In 2027, ALXO's EPS is forecast to hit -$0.73 (min: -$0.85, max: -$0.50).

What is ALXO's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ALXO) forecast ROE is -61.72%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.